http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김상욱(Sang Wook Kim),송태호(Tae Ho Song),김철우(Cheul Woo Kim),권기익(Ki Ik Kwon),유언호(Un Ho Ryoo) 대한내과학회 1994 대한내과학회지 Vol.47 No.1
N/A Background: Hypertension is a major risk factor for atherosclerotic vascular disease. Many antihypertensive drugs are known to alter lipoprotein metabolism and this may override the benefit of blood pressure reduction. The purpose of this study is to evaluate the effects of the antihypertensive therapy in serum lipid. Method: The clinical study was done on 200 patients with hypertension who treated with esidrex, beta-blocker, or esidrex plus beta-blocker as an antihypertensive medication. The patients were divided into three groups according to the antihypertensive regimens. The serum lipid values were checked before and during antihypertensive therapy. Average follow up period of serum lipid was about 2 years. Results : 1) The serum lipid values before antihypertensive therapy were triglyceride 177±125 mg/dl, HDL-cholesterol 42±12 mg/dl, total cholesterol 230±50 mg/dl, and 1 year after antihypertensive therapy, triglyceride 233±134 mg/dl, HDL-cholesterol 43±22 mg/dl, total cholesterol 235±47 mg/dl, and 2 year after antihypertensive therapy, triglyceride 243±172 mg/dl, HDL-cholesterol 45±11 mg/dl, total cholesterol 233±40 mg/dl. The serum triglyceride and total cholesterol were increased significantly after antihypertensive therapy. 2) In 30 patients with esidrex therapy, the serum total cholesterol was elevated than the pretreatment value (p<0.05); pretreatment value 228±59 mg/dl, 6 months 233±53 mg/dl, 1 year 239±53 mg/dl, 2 year 238±39 mg/ dl. 3) In 81 patients with beta-blocker therapy, the serum triglyceride was elevated than the pretreatment value (p<0.05); pretreatment value 164±67 mg/dl, 6 months 183±72 mg/dl, 1 year 245±75 mg/dl, 2 year 205±84 mg/ dl. 4) In 89 patients with esidrex plus beta-blocker therapy, the serum total cholesterol was elevated than pretreatment value (p<0.05); pretreatment value 210±45 mg/dl, 6 month 264±50 mg/dl, l year 237±53 mg/dl, 2 year 225±48 mg/di, and triglyceride was also elevated; pretreatment value 163±87 mg/dl, 6 months 195±76 mg/dl, 1 year 208±80 mg/dl, 2 year 211±85 mg/ dl, But the serum HDL cholesterol was not elevated significantly. Conclusion : The esidrex therapy was associated with the elevation of serum total cholesterol and beta- blocker therapy was associated with the elevation of serum triglyceride. The serum total cholesterol and triglyceride were increased during esidrex plus beta-blocker therapy.
당뇨병 환자에서 비관혈적 방법에 의한 좌심실기능 평가에 관한 연구
방준경(Joon Kyung Bang),현창훈(Chang Hun Hyun),이병직(Byung Jik Lee),류왕성(Wang Seong Ryu),권기익(Ki Ik Kwon),강창순(Chang Soon Kang),유언호(Un Ho Ryoo) 대한내과학회 1987 대한내과학회지 Vol.32 No.4
N/A Diabetes mellitus has been clearly identified as an independent risk factor in coronary heart diasase, sudden death, congestive heart failure, stroke, and peripheral vascular disease. The diabetic patient is twice as prone to develop heart disease as the general population. Recently the term Diabetic cardiomyopathy has been appeared in medical publications. This term imply the existence of a specific diabetic heart disease, a new nosological entity that has been growing out of several studies performed during the last few years by research workers in diabetes. The assessment of left ventricular function as an index of potential myocardial involvement in diabetic patients without clinical evidence of myocardial ischemia or other cardiovascular abnormalities has become increasingly important. To examine left ventricular function in diabetic patients without clinical evidence of cardiac involvement, eleetrocardiogram, phonocardiogram, carotid pulse tracing, echocardiogram, apexardiogram, and the first derivative of the apexcardiogram were performed in normal subjects and 16 diabetic patients. The results were as follows. 1) Corrected R to first peak interval was 96.1±25.9 msec in diabetic group and 66.3±14.8 msec in control group (p<0.05), height ratio was 52.9±7.4% in diabetic group and 56.5±4.0% in control group (p<0.05). S to second peak interval was not significant value. 2) Pre-ejection period was 85.9±27.2 msec in diabetic group and 40.9±12.2 msec in control group (p<0.05), left ventricular ejection time was 302.5±39.9 msec in diabetic group and 340.0±20.7 msec in control group (p<0.05). Electromechanical systole was not significant value. 3) A-MVO was 90.4±19.1 msec in diabetic group and 64.8±13.7msec in control group (p<0.05), ejection fraction was 59.5±11.2% in diabetic group and 68.5±7.5% in control group (p<0.05). Based on these findings, mechanocardiography for assessment of left ventricular function may be utilized as a good index of potential myocardial involvement in diabetic patients.
차영주,류왕성,김용성,서양관,현창훈,권기익,유언호 대한내과학회 1988 대한내과학회지 Vol.35 No.3
A study of a family with a hereditary deficiency of antithrombin III (AT III), as measured by an immunoassay, is reported. The propositus was a 37-year-old male with a 3-year history of recurrent attacks of deep vein thrombosis of the lower legs. A study of his family revealed a disposition to thromboembolism on the parental side and an autosomal dominant pattern of inheritance, involving five of ten siblings. They have suffered from frequent episodes of venous thrombosis of the lower legs.